Lyell Immunopharma (LYEL) Total Liabilities (2020 - 2026)

Lyell Immunopharma (LYEL) has 7 years of Total Liabilities data on file, last reported at $77.0 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities fell 17.49% year-over-year to $77.0 million; the trailing twelve-month figure through Mar 2026 stood at $77.0 million (down 17.49% YoY), and the FY2025 full-year result was $91.8 million, down 14.98% from the prior year.
• Total Liabilities fell to $77.0 million in Q1 2026, from $91.8 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $190.9 million in Q1 2022 to a low of $77.0 million in Q1 2026.
• A 5-year average of $105.7 million and a median of $95.1 million in 2023 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities plunged 49.37% in 2023 and climbed 13.63% in 2024, its largest moves.
• Tracing LYEL's Total Liabilities over 5 years: stood at $104.3 million in 2022, then dropped by 8.85% to $95.1 million in 2023, then advanced by 13.63% to $108.0 million in 2024, then retreated by 14.98% to $91.8 million in 2025, then slipped by 16.21% to $77.0 million in 2026.
• Business Quant data shows LYEL's Total Liabilities at $77.0 million in Q1 2026, $91.8 million in Q4 2025, and $78.8 million in Q3 2025.